VRCA — Verrica Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $48.34m
- $60.35m
- $7.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -433.81% | ||
| Return on Equity | n/a | ||
| Operating Margin | -772.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 12 | 9.03 | 5.12 | 7.57 | 20.17 | 34.56 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Directors
- Paul Manning CHM (65)
- Ted White PRE (56)
- Terry Kohler CFO (43)
- Christopher Hayes GCN (57)
- Joe Bonaccorso OTH (57)
- Gary Goldenberg OTH (44)
- Sean Stalfort DRC (51)
- Craig Ballaron IND (60)
- Lawrence Eichenfield IND (63)
- Diem Nguyen IND
- Mark Prygocki IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 3rd, 2013
- Public Since
- June 15th, 2018
- No. of Shareholders
- 15
- No. of Employees
- 71
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 92,490,993
- Address
- 44 West Gay Street, Suite 400, WEST CHESTER, 19380
- Web
- https://verrica.com/
- Phone
- +1 4844533300
- Auditors
- KPMG LLP
Upcoming Events for VRCA
Q3 2025 Verrica Pharmaceuticals Inc Earnings Release
Similar to VRCA
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Verrica Pharmaceuticals share price?
As of Today at 23:57 UTC, shares in Verrica Pharmaceuticals are trading at $0.52. This share price information is delayed by 15 minutes.
How has the Verrica Pharmaceuticals share price performed this year?
Shares in Verrica Pharmaceuticals last closed at $0.52 and the price had moved by -92.76% over the past 365 days. In terms of relative price strength the Verrica Pharmaceuticals share price has underperformed the S&P500 Index by -93.6% over the past year.
What are the analyst and broker recommendations for Verrica Pharmaceuticals?
The overall consensus recommendation for Verrica Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Verrica Pharmaceuticals dividend yield?
Verrica Pharmaceuticals does not currently pay a dividend.
Does Verrica Pharmaceuticals pay a dividend?
Verrica Pharmaceuticals does not currently pay a dividend.
When does Verrica Pharmaceuticals next pay dividends?
Verrica Pharmaceuticals does not currently pay a dividend.
How do I buy Verrica Pharmaceuticals shares?
To buy shares in Verrica Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Verrica Pharmaceuticals?
As of the previous close price of $0.52, shares in Verrica Pharmaceuticals had a market capitalisation of $48.34m.
Where are Verrica Pharmaceuticals shares listed?
Here are the trading details for Verrica Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VRCA
What kind of share is Verrica Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Verrica Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Verrica Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Verrica Pharmaceuticals is $4.00. That is 665.4% above the last closing price of $0.52.
Analysts covering Verrica Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
Find out moreWhat is the trend in the Verrica Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verrica Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -26.92%.
As of the last closing price of $0.52, shares in Verrica Pharmaceuticals were trading -38.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Verrica Pharmaceuticals PE Ratio?
The Verrica Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Verrica Pharmaceuticals?
Verrica Pharmaceuticals' management team is headed by:
- Paul Manning - CHM
- Ted White - PRE
- Terry Kohler - CFO
- Christopher Hayes - GCN
- Joe Bonaccorso - OTH
- Gary Goldenberg - OTH
- Sean Stalfort - DRC
- Craig Ballaron - IND
- Lawrence Eichenfield - IND
- Diem Nguyen - IND
- Mark Prygocki - IND